IFITM3-specific antibody reveals IFN preferences and slow IFN induction of the antiviral factor IFITM3 in humans.

Wellington D., Yin Z., Abdel-Haq A., Zhang L., Forbester J., Kite K., Rajapaksa U., Laurenson-Schafer H., Makvandi-Nejad S., Jin B., Bowes E., Manoharan K., Maldonado-Perez D., Verrill C., Humphreys IR., Dong T.

Using a specific antibody, we found that expression of the viral restriction factor IFITM3 differs across cell types within the immune compartment with higher expression in myeloid rather than lymphoid cells. IFITM3 expression was increased following IFN stimulation, mostly type I, in immune cells, with the exception of T cells.

DOI

10.1002/eji.202048706

Type

Journal article

Journal

European journal of immunology

Publication Date

03/2021

Volume

51

Pages

742 - 745

Addresses

MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, Oxford University, Oxford, UK.

Keywords

Lymphocytes, CD4-Positive T-Lymphocytes, Cell Line, Cell Line, Tumor, Humans, RNA-Binding Proteins, Interferon Type I, Membrane Proteins, Antiviral Agents, HEK293 Cells, A549 Cells

Permalink Original publication